Toggle light / dark theme

CRISPR-COPIES: New Tool Accelerates and Optimizes Genome Editing

CRISPR/Cas systems have undergone tremendous advancement in the past decade. These precise genome editing tools have applications ranging from transgenic crop development to gene therapy and beyond. And with their recent development of CRISPR-COPIES, researchers at the Center for Advanced Bioenergy and Bioproducts Innovation (CABBI) are further improving CRISPR’s versatility and ease of use.

“CRISPR-COPIES is a tool that can quickly identify appropriate chromosomal integration sites for genetic engineering in any organism,” said Huimin Zhao, CABBI Conversion Theme Leader and Steven L. Miller Chair of Chemical and Biomolecular Engineering (ChBE) at the University of Illinois. “It will accelerate our work in the metabolic engineering of non-model yeasts for cost-effective production of chemicals and biofuels.”

Gene editing has revolutionized scientists’ capabilities in understanding and manipulating genetic information. This form of genetic engineering allows researchers to introduce new traits into an organism, such as resistance to pests or the ability to produce a valuable biochemical.

Scientists develop new technology to identify individual full-length human proteins

In a study published in Nature Nanotechnology, scientists from Delft University of Technology present a new technique to identify proteins. Proteins carry out essential functions in our cells, while playing a crucial role in diseases like cancer and COVID-19 infection. The researchers identify proteins by reading out the fingerprint, and comparing the fingerprint to patterns from a database.

Using this new technology, the researchers can identify individual, intact, full-length proteins, preserving all its information. This can shed light on the mechanisms behind many different diseases and allows earlier diagnosis.

Fluicell partners with Swedish researchers to 3D bioprint complex brain cell structures

Scientists from medical tech company Fluicell have partnered with clinical R&D firm Cellectricon and the Swedish Karolinska Institutet university to 3D bioprint neural cells into complex patterns.

Using the microfluidic printheads featured on Fluicell’s Biopixlar platform, the researchers were able to accurately arrange rat brain cells within 3D structures, without damaging their viability. The resulting cerebral tissues could be used to model the progress of neurological diseases, or to test the efficacy of related drugs.

“We’ve been using Biopixlar to develop protocols for the printing of different neuronal cells types, and we are very pleased with its performance,” said Mattias Karlsson, CEO of Cellectricon. “This exciting technology has the potential to open completely new avenues for in-vitro modeling of a wide range of central and PNS-related diseases.”

AI-powered neurotech developer Elemind emerges from stealth with backing from Bezos, Gates

It’s electric! A startup emerged from stealth this week with grand plans to pioneer a new form of neurotech dubbed “electric medicine.”

Elemind’s approach centers on artificial intelligence-powered algorithms that are trained to continuously analyze neurological activity collected by a noninvasive wearable device, then to deliver through the wearable bursts of neurostimulation that are uniquely tailored to those real-time brain wave readings.

Cancer breakthrough as doctors celebrate new ‘wonder drug’

Scientists have welcomed a “truly wonderful” new drug for a hard-to-treat and aggressive form of cancer.

Researchers led by a team at Queen Mary University of London said their new treatment “quadrupled” three-year survival rates and increased average survival by 1.6 months.

Academics said that the new drug, which works by cutting off the tumour ’s food supply, is the first of its type for mesothelioma in 20 years.

Shocking Truth About AI, Chronic Disease, Toxins, Diet & Lifestyle For Longevity | Eric Topol

https://music.youtube.com/watch?v=n_LefGJgOJ8&si=UoInnL8Xy_wsXv_

Currently listening to this. He’s pretty decent, up there with Dr Daniel Amen in advancement/ideas. I barely started this episode but it seems AI can help in medicine and there’s more in this podcast concerning our personal health. This is some key issues for longevity.


Get my FREE guide 3 Steps to Reverse Aging when you sign up for my weekly health picks 👉 https://bit.ly/IncreaseHealthspan.

View the Show Notes For This Episode: https://bit.ly/ep-855

Dr. Eric Topol is the Founder and Director of the Scripps Research Translational Institute, Professor of Molecular Medicine, and Executive Vice-President of Scripps Research. He has published over 1,200 peer-reviewed articles with more than 330,000 citations, was elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. His principal scientific focus has been on individualized medicine using genomic, digital, and AI tools.

This episode is brought to you by Rupa Health, Pendulum, Thrive Market, and Fatty15.